Omnicell(US:OMCL)2020-07-30 16:44Medication Management Challenges & Vision - Medication errors lead to 20-30% of prescriptions never being filled[10], resulting in a $300 billion annual loss due to non-adherence[10] - Suboptimal medication outcomes contribute to a $485 billion gross medication spend[14] - The industry envisions a shift from manual intervention and paper-based processes to integrated systems with limited human intervention, aiming for optimized outcomes[27] Omnicell's Solutions & Differentiation - Omnicell aims to accelerate pharmacy to perfection and be the care provider's most trusted partner[8, 24] - Omnicell is the only tech provider with a comprehensive portfolio across the care continuum, serving over half of the Top 300 U S Health Systems[24] - Omnicell's XT Series replacement cycle is early, with 26% penetration in 2Q20[28] Financial Goals & Growth - Omnicell targets long-term organic revenue growth of 10%-12% post-pandemic[73] - The company aims for a long-term non-GAAP operating margin of 18% post-pandemic[74] - Omnicell anticipates Q3 2020 non-GAAP total revenues of $204-$212 million, with product revenues of $143-$149 million and service revenues of $61-$63 million[82]